Impedimed Ltd has released a press release.
New Version of NCCN Guidelines for Breast Cancer
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Impedimed
- ImpediMed Announces Appointment of Managing Director and CEO
- ImpediMed Announces Management Reorganisation
- AstraZeneca Further Extends Clinical Trial Contract
- Appendix 4C & Quarterly Activities Report - Sep-22 Qtr
- New Corporate Oncology Account with GenesisCare
Later from Impedimed
- Appendix 4C & Quarterly Activities Report - Dec-22 Qtr
- S&P DJI Announces March 2023 Quarterly Rebalance
- NCCN Guidelines Now Recommend Bioimpedance Spectroscopy
- Appendix 4C & Quarterly Activities Report - Mar-23 Qtr
- SOZO Pro Achieves Clearance by U.S. FDA
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed